Melissa Laporte
Adult Health · Wilkes Barre, PANPI 1023028289
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $51,579 of the $59,088 with a category attached, or 87.3%. Novo Nordisk accounts for 80.0% of it on its own, with 8 other manufacturers making up the rest. Among adult health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $547.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$47K
- Sanofi-aventis U.S. LLC$9K
- Medtronic$2K
- Dexcom, Inc.$318
- Tandem Diabetes Care, Inc.$124
- Abbott$93
- plus $179 from 3 others
What the payments were for
- Speaking & faculty fees$51,57987%
- Travel & lodging$3,0415%
- Food & beverage$4,4368%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 65 | $47,280 |
| Sanofi-aventis U.S. LLC | 15 | $8,867 |
| Medtronic | 18 | $2,228 |
| Dexcom, Inc. | 4 | $318 |
| Tandem Diabetes Care, Inc. | 2 | $124 |
| Abbott | 1 | $93 |
| Nestle Healthcare Nutrition Inc. | 1 | $80 |
| BETA Bionics, Inc. | 1 | $79 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$26,634
- Ozempic$15,617
- TZIELD$8,420
- MINIMED 780G$1,818
- DEXCOM G6 TRANSMITTER$102
How this compares
$59,088 in reported general payments places this provider in the 95th percentile of 899 adult health providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 470 | $735,036 |
| JardianceEmpagliflozin | 384 | $443,869 |
| TrulicityDulaglutide | 122 | $188,725 |
| MounjaroTirzepatide | 120 | $156,342 |
| FarxigaDapagliflozin Propanediol | 125 | $118,106 |
| Tresiba Flextouch U-200Insulin Degludec | 51 | $114,485 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 128 | $105,314 |
| Tresiba Flextouch U-100Insulin Degludec | 82 | $81,043 |
| Novolog FlexpenInsulin Aspart | 232 | $78,442 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 44 | $77,224 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $65,628 |
| RybelsusSemaglutide | 34 | $64,148 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 51 | $63,408 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 63 | $37,955 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 20 | $37,726 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $47,280 | $834,333586 claims |
| Sanofi-aventis U.S. LLCLantus, Soliqua 100-33 | $8,867 | $22,44674 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 899 adult health providers in Pennsylvania.
Other adult health in Wilkes Barre
- Beth SandyPhiladelphia$924K
- Jennifer MondilloSchwenksville$396K
- Diane NewmanPhiladelphia$343K
- Elizabeth FaustDouglassville$342K
- Abigail SmithPhiladelphia$302K
- Jean CainAllentown$214K
- Jennifer KeeleyWexford$97K
- Debra EvansFarrell$85K
- Bethann MallonBlue Bell$65K
- Catherine HoldsworthPhiladelphia$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.